מן הרשת 31.03.202412:51 Genitourinary toxicity in patients receiving TURP for clinically localized prostate cancer Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review Uro Today
מן הרשת 31.03.202412:49 Hormonal Therapy Plus SBRT for Advanced Prostate Cancer Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer The ASCO Post
מן הרשת 31.03.202412:45 Differential Effectiveness by Risk Group? Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations European Urology Oncology
מן הרשת 31.03.202412:44 Incidence of pulmonary toxicity in bleomycin-containing regimens for testicular cancer with and without the use of growth factor Uro Today
מן הרשת 31.03.202412:43 Stratification of Patients with Renal Cell Carcinoma by the Abundance of Sarcomatoid Features Reveals Differences in Survival and the Underlying Pathobiology Uro Today
מן הרשת 31.03.202412:42 The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection Uro Today
מן הרשת 31.03.202412:41 Nadir PSA as a Prognostic Marker for Metastatic Hormone-Sensitive Prostate Cancer Recent research has demonstrated the effectiveness of new treatments and prognostic markers, including nadir prostate-specific antigen (PSA) level, for metastatic hormone-sensitive prostate cancer (HSPC) GUOncology Now
מן הרשת 31.03.202412:40 The Overall Survival Benefit in EV-302 Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma? European Urology Oncology
מן הרשת 31.03.202412:39 Stereotactic ablative body radiotherapy for primary kidney cancer The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial The Lancet Oncology
מן הרשת 31.03.202412:37 Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer To address cancer-specific mortality free-survival (CSM-FS) differences in patients with urothelial carcinoma of the urinary bladder (UCUB) vs non-UCUB who underwent trimodal therapy (TMT), according to organ confined (OC: T2N0M0) vs non-organ confined (NOC: T3-4NanyM0 or TanyN1-3M0) clinical stages Uro Today
מן הרשת 31.03.202412:34 Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis This pooled analysis of patient-level data from trials evaluated the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) with or without cytoreductive nephrectomy (CN) prior to a combination of immune checkpoint inhibitor (ICI) and anti-angiogenic therapy Uro Today
מן הרשת 31.03.202412:32 Hormonal Therapy Plus SBRT for Advanced Prostate Cancer Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in European Urology The ASCO Post
מן הרשת 31.03.202412:31 Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases Uro Today
מן הרשת 28.03.202411:51 A novel model to predict recurrence-free survival and melanoma-specific survival Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis The Lancet Oncology
מן הרשת 28.03.202411:49 First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma In an event more than three decades in the making, the Food and Drug Administration (FDA) has approved lifileucel (Amtagvi), the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs National Cancer Institue
תגובות אחרונות